 (OTC:AHLTS) Stock, Quote.Headers.trade-ideas

Biotech

News

Events

General

ALXO

ALX Oncology Announces Oral Presentation At 2025 ASCO Gastrointestinal Cancers Symposium Today

For speculative traders seeking exposure to daily sentiment swings, the new year seemingly offers plenty of ammunition. With President Donald Trump entering his second term, the outspoken leader wasted no time reshaping U.S. policy with a<a href="https://www.benzinga.com/government/regulations/25/01/43084601/trump-day-1-executive-order-tsunami-incoming-heres-what-hes-signing-first"> flurry of executive orders</a>. These actions encompass a range of subjects, including energy, immigration, inflation, social policies and trade.
Thanks to a unique vision that sharply contrasts with the prior Biden administration, several sectors rose to the forefront. Perhaps the most prominent example is the cryptocurrency market. Ever since Trump's electoral victory last November, the ecosystem for blockchain-derived assets has been invigorated. Throughout the campaign trail, the former real estate mogul openly and enthusiastically<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43062997/exclusive-how-donald-trumps-crypto-plans-will-bitcoin-xrp-solana"> embraced decentralized digital assets</a>.
In addition, President Trump's pro-business mandates – which notably include deregulation and lower corporate taxes – may reinvigorate a risk-on framework. Emerging industries, such as quantum computing and space economy specialists, have been clear beneficiaries of the conducive environment. These factors combine with a greater emphasis on building out<a href="https://www.benzinga.com/25/01/42862503/3-digital-infrastructure-etfs-in-focus-as-trump-reveals-billion-dollar-data-center-construction-plan"> digital infrastructures</a> to create plenty of upside opportunities for investors to find.
Still, not everything is leaning toward the northward direction. Given the sharp pivot from the prior administration, there are bound to be losers. Among them sit market segments tied to renewable energy. In particular,<a href="https://www.benzinga.com/trading-ideas/movers/25/01/43147598/ev-stocks-are-falling-today-whats-going-on"> shares of electric vehicle stocks faltered recently</a> amid radical changes under Trump 2.0. With the president promising to "drill, baby, drill," the<a href="https://www.benzinga.com/government/regulations/25/01/43097430/trumps-drill-baby-drill-era-begins-oil-prices-tumble-us-energy-stocks-edge-up"> move toward hydrocarbons</a> has caused anxiety among green energy proponents.
Moreover, elements outside of direct executive control may cause the equities arena to stumble. Perhaps most worryingly,<a href="https://www.benzinga.com/trading-ideas/25/01/43064849/4-stocks-to-buy-for-higher-for-longer-interest-rates"> interest rates could stay elevated</a> for longer than desired, in large part due to a red-hot labor market. When these factors are seen in conjunction with a<a href="https://www.benzinga.com/economics/macro-economic-events/25/01/42896114/us-2025-recession-odds-plummet-good-news-or-warning-sign"> potential misreading of broader risk</a>, investors could be facing a surprisingly dynamic ecosystem.
The Direxion ETFs: To put it simply, the market could be liable to move in any direction, depending on the prevailing winds. With that in mind, the most adventurous and aggressive investors may consider ultra-leveraged exchange-traded funds. For the optimists, the Direxion Daily Small Cap Bull 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNA#NYSE">TNA</a>) seek the daily investment results of 300% of the performance of the Russell 2000 index.
With exposure to the TNA ETF, traders can potentially enjoy significant upside without having to buy call options. Instead, market participants can pick up units of TNA, similar to any publicly traded enterprise. In the same vein, bearish speculators can acquire units of the Direxion Daily Small Cap Bear 3X Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TZA#NYSE">TZA</a>) rather than needing to resort to purchasing put options.
While the Direxion 3X ETFs are convenient, investors should note the volatility risks involved in these financial products. As Direxion's<a href="https://www.direxion.com/product/daily-small-cap-bull-bear-3x-etfs"> website</a> states, these leveraged ETFs are designed for trading exposure lasting no longer than one day.
The TNA ETF: Although the chart for the Daily Small Cap Bull ETF is a choppy affair, anticipation of a much more business-friendly environment has bolstered sentiment recently.
<ul>
<li>Over the trailing one-month period, TNA gained almost 8% of value, driving the price action above the 200-day moving average (DMA).</li>
<li>Technical resistance lies at the 50 DMA, which currently stands a bit above $48. For the bulls, this will be the next natural target.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXf2tMb0MYkL5HZuEUDtUKPeZwaP9R5TSmRfBmockq0UJfV14B2-jV3iOd2PMgBfcrd3y4mYg8_V6PqVgu54CBeeufT8yoxyiyBY75eXgZBSc4VfiQXyFUze6jReRwoJn-4ejiKF8Q?key=U_Y0u8R0Y_cA_5nvA0CDLRBd" alt="" /></figure>
The TZA ETF: A volatile canvas, the Daily Small Cap Bear ETF has struggled over the past 52 weeks, losing more than 45%. However, an economic shock could revitalize the inverse fund.
<ul>
<li>For proponents of the TZA ETF, it's vital for the bear fund to keep its head above the psychologically and technically significant $10 level.</li>
<li>Right now, the 50 DMA provides support for TZA. Moving forward, the upside target is where the 200 DMA stands at a few clicks above $15.</li>
</ul>
<figure class="wp-block-image"><img decoding="async" src="https://lh7-rt.googleusercontent.com/docsz/AD_4nXcTGV5-x-BFejfGg3BKhhEbig7erIttWKGg-gXPRU-aAQut2XepCP7dn1qpfHH4zSqsdiNgU8l6wzmdBoiLpQMeueWHPDdBxOPDLkI1G6ZP4TjUr7mVBr7zMJej1Gz8hexIytKG0g?key=U_Y0u8R0Y_cA_5nvA0CDLRBd" alt="" /></figure>
Featured image by <a href="https://pixabay.com/users/geralt-9301/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=8477673">Gerd Altmann</a> from <a href="https://pixabay.com/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=8477673">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

ETFs

Trump 2.0 Presents Both Promise And Pitfalls For Direxion's Small Cap Bull And Bear Funds

With winter hosting and game day celebrations in full swing, Uber Eats (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) today announces a new partnership with Wegmans Food Markets, Inc., bringing the beloved supermarket's products directly to customers' doors. Starting this month, Uber Eats users will have the convenience of ordering from Wegmans' expansive collection of high-quality groceries through the app, increasing consumer access to the company's offerings.

UBER

Uber Eats Partners With Wegmans To Expand Grocery Delivery

Barclays analyst Nicholas Campanella maintains Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) with a Overweight and lowers the price target from $76 to $67.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Edison Intl, Lowers Price Target to $67

Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, celebrates the successful launch of Firefly Aerospace's Blue Ghost Mission 1. Rocket Lab is supporting Blue Ghost's 45-day journey to the Moon with the Company's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.rocketlabusa.com%2Fspace-systems%2Fspace-software%2F&amp;esheet=54188878&amp;newsitemid=20250123312409&amp;lan=en-US&amp;anchor=MAX+Flight+and+MAX+Ground+Data+Software+suites&amp;index=1&amp;md5=2e454faa0cb6bfcb9ef89396a53487b9">MAX Flight and MAX Ground Data Software suites</a>.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20250123312409/en/">https://www.businesswire.com/news/home/20250123312409/en/</a>
Firefly Aerospace's Blue Ghost 1 lunar lander features Rocket Lab's software and solar solutions. Image Credit: Firefly Aerospace
Rocket Lab also provided three high-efficiency photovoltaic assemblies, comprising our interconnected space-grade solar cells, mounted on the lander's sides and top deck, providing 400 W of power over 1,470 operational hours to support the lander during its journey to the lunar surface.
During the Blue Ghost mission, the Rocket Lab team will also support Firefly's execution of multiple burns and management of orbit determination and attitude control throughout the cruise and landing phases of the mission.
Firefly's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffireflyspace.com%2Fmissions%2Fblue-ghost-mission-1%2F&amp;esheet=54188878&amp;newsitemid=20250123312409&amp;lan=en-US&amp;anchor=Blue+Ghost+mission&amp;index=2&amp;md5=62f3c29dc61520519b7351564ef7c28c">Blue Ghost mission</a> is advancing lunar science and exploration by delivering state-of-the-art instruments and technology demonstrations to the Moon as part of NASA's Commercial Lunar Payload Services (CLPS) program.

RKLB

Rocket Lab Announces Successful Launch Support For Firefly Aerospace's Blue Ghost Mission 1 To Moon; Provides Software, Solar Solutions, And Manages Orbit And Attitude Control; Part Of NASA's Commercial Lunar Payload Services Program

Contracts

LDOS

Leidos Announces Follow-On TSA Contract To Maintain 12,000+ Units Of Transportation Security Equipment; Eight-Year Contract Has Maximum Value Of $2.6B

Barclays analyst Raimo Lenschow maintains ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) with a Equal-Weight and lowers the price target from $12 to $11.

Barclays Maintains Equal-Weight on ZoomInfo Technologies, Lowers Price Target to $11

– Company Reaffirms Outlook for Positive Adjusted EBITDA1 by Q2 2025 –
– Company Provides Update on Restatement Effort and Regulatory Inquiry –
Evolv Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) (the "Company"), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today provided an update on select strategic metrics for the three-month period ended December 31, 20242. The Company also provided an update on its pending restatement effort and other regulatory matters.

Guidance

EVLV

Evolv Technology Reaffirms Outlook For Positive Adjusted EBITDA By Q2 2025; Provides Update On Restatement Effort And Regulatory Inquiry

Textron Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXT#NYSE">TXT</a>) reported downbeat fourth-quarter revenue and issued FY25 EPS guidance below <a href="https://www.benzinga.com/news/earnings/25/01/43127009/textron-reports-mixed-q4-faces-challenges-in-aviation-and-industrial-segments">estimates on Wednesday.</a>
Sales grew to $3.613 billion, missing the consensus of $3.81 billion, although adjusted EPS of $1.34 was in line with the consensus.
Textron expects GAAP EPS from continuing operations of $5.19-$5.39 or $6.00 -$6.20 on an adjusted basis (vs. consensus of $6.42) and revenue of $14.7 billion (vs. $14.757 billion estimate).
Textron projects cash flow from continuing operations of the manufacturing group of $1.2 billion and $1.3 billion.
Scott C. Donnelly, Chairman and CEO, said, "While a work stoppage at Textron Aviation impacted our 2024 financial results, we saw strong order activity, aftermarket growth, and continued new product development activities with the announcement of the Gen3 family of light jets."
Textron shares fell 3.4% to close at $78.41 on Wednesday.
These analysts made changes to their price targets on Textron following earnings announcement.
<ul>
<li>Morgan Stanley analyst Kristine Liwag maintained Textron with an Equal-Weight rating and lowered the price target from $86 to $82.</li>
<li>Baird analyst Peter Arment maintained Textron with an Outperform and lowered the price target from $100 to $92.</li>
</ul>
Considering buying TXT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080132/image-172-1024x595.png" alt="" class="wp-image-746722" style="width:623px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080132/image-172-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080132/image-172-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080132/image-172-768x446.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080132/image-172.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Earnings

Markets

Textron Analysts Slash Their Forecasts After Weak Revenue

Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBCP#NASDAQ">IBCP</a>) reported quarterly sales of $42.85 million which met the analyst consensus estimate. This is a 6.83 percent increase over sales of $40.11 million the same period last year.

IBCP

Independent Bank Q4 Sales $42.85M Inline

Editor&#8217;s Note: This story has been updated with a response from a Bitwise spokesperson.
Cryptocurrency index fund manager Bitwise Asset Management filed for a Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) exchange-traded fund on Wednesday, prompting analysts to forecast big returns for the dog-themed meme coin.
What happened: Bitwise submitted the ETF filing to Delaware's Department of State's Division of Corporations. The filing was made under the entity name BITWISE DOGECOIN ETF, with CSC Delaware Trust Company listed as the registered agent.
A Bitwise spokesperson told <a href="http://pro.benzinga.com">Benzinga</a> that the filing was legitimate. Meanwhile, leading ETF analyst Eric Balchunas also approved the authenticity of the filing on X.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitwise Doge ETF likely coming soon.. and yes I checked and this is def legit (vs some whack job committing forgery for a quick pump a la BlackRock XRP that one time). <a href="https://t.co/MxoswD0IFy">pic.twitter.com/MxoswD0IFy</a>
&mdash; Eric Balchunas (@EricBalchunas) <a href="https://twitter.com/EricBalchunas/status/1882202309293433217?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43151588/cathie-wood-was-asked-if-she-would-buy-trump-coin-heres-what-she-said">Cathie Wood Was Asked If She Would Buy TRUMP Coin, Here&#8217;s What She Said</a>
The Delaware registration is typically the first step in the ETF listing process and still requires an official filing with the SEC.&nbsp;
Similar listings were seen previously for iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) and iShares Ethereum Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>), and even the <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41134111/after-bitcoin-ethereum-an-xrp-etf-bitwise-registers-filing-in-delaware-amid-rippe-vs-sec-l">XRP ETF</a> filed by Bitwise last year.
Following the filing, Ali Martinez, a well-known cryptocurrency analyst and trader, issued a massively bullish price target of $15 for Dogecoin. At the current price, this pointed to a staggering upside of 4140.88%
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> ETF will send it to $15! <a href="https://t.co/4peKi93NZX">https://t.co/4peKi93NZX</a> <a href="https://t.co/gRqDdoXhob">pic.twitter.com/gRqDdoXhob</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1882196406800445537?ref_src=twsrc%5Etfw">January 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: Bitwise&#8217;s registration comes after REXShares and Osprey filed numerous ETF applications with the SEC earlier this week, <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43105356/meme-coin-supercycle-dogecoin-trump-bonk-futures-etf-applications-filed">including one</a> for Dogecoin.
These filings were factored into prediction markets, as the odds of a Dogecoin ETF being approved in 2025 <a href="https://polymarket.com/event/doge-etf-approved-in-2025">increased </a>from 36% to 53% on Polymarket before stabilizing at 48% as of this writing.
Meanwhile, the iconic Shiba Inu imagery, a symbol closely tied to Dogecoin's popularity, <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43140690/dogecoin-drops-6-after-doge-department-removes-logo">was removed</a> from the Elon Musk-headed Department of Government Efficiency&#8217;s website.
Price Action: At the time of writing, Dogecoin was exchanging hands at $0.3535, down 3.07% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Year-to-date, the cryptocurrency has gained 8.43%.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/01/43150952/blackrock-ceo-larry-fink-says-bitcoin-could-rise-to-700000-on-monetary-debasement-political-instability-fears">Blackrock CEO Larry Fink Says Bitcoin Could Rise To $700,000 On Fiat Fears: &#8216;If You&#8217;re Frightened Of The Debasement…&#8217;</a></li>
</ul>
Image via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

ETHA

IBIT

Bets Favoring Dogecoin ETF Approval In 2025 Jump After Bitwise's Delaware Filing—Top Trader Paints Over 4000% Upside For Memecoin (UPDATED)

In the last three months, 11 analysts have published ratings on Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>), offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $79.0, a high estimate of $96.00, and a low estimate of $64.00. Observing a 8.82% increase, the current average has risen from the previous average price target of $72.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1737637292_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Unum Gr. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$85.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$96.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$76.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$66.00</td>
<td>$59.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Unum Gr. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Unum Gr compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Unum Gr's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Unum Gr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UNM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Unum Gr analyst ratings.</a>
<h2>All You Need to Know About Unum Gr</h2>
Unum Group is a provider of group and individual income protection insurance products in the United States, the United Kingdom, Poland, and other countries. It is the largest domestic disability insurer, with the majority of premiums generated from employer plans. The company also offers a complementary portfolio of other insurance products, including long-term care insurance, life insurance, and employer- and employee-paid group benefits. It has the following operating business segments: Unum US, Unum International, and Colonial Life. The majority of the revenue is earned from the Unum US segment. The firm markets its products primarily through brokers.
<h3>Understanding the Numbers: Unum Gr's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Unum Gr's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 4.34%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Unum Gr's net margin is impressive, surpassing industry averages. With a net margin of 20.16%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Unum Gr's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Unum Gr's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.02%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.32.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 11 Analyst Ratings Have To Say About Unum Gr

In the latest quarter, 8 analysts provided ratings for Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $45.12, a high estimate of $56.00, and a low estimate of $40.00. Surpassing the previous average price target of $41.14, the current average has increased by 9.67%.
<img src="https://www.benzinga.com/files/images/story/2025/1737637279_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Ally Financial is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$40.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$44.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$56.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ally Financial. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Ally Financial compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Ally Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Ally Financial's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALLY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Ally Financial analyst ratings.</a>
<h2>Delving into Ally Financial's Background</h2>
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
<h3>Understanding the Numbers: Ally Financial's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ally Financial's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 5.62%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Ally Financial's net margin is impressive, surpassing industry averages. With a net margin of 14.39%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.76%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.17%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.48, Ally Financial adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLY

Forecasting The Future: 8 Analyst Projections For Ally Financial

Stock Split

Conduit Pharmaceuticals Board Approves 1-for-100 Reverse Stock Split, Will Become Effective Jan. 24 At 5:00 pm ET

Expects to Complete Enrollment of First 25 Patients in Phase 2 Expansion Study During Second Half of 2025 for Interim Analysis
Acclaim-3 Study Has FDA Orphan Drug and Fast Track Designations
AUSTIN, Texas, Jan. 23, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4346156-1&amp;h=1938435830&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the first patient has been enrolled and dosed in the Phase 2 expansion portion of the Company's Acclaim-3 clinical study of Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid) in combination with Tecentriq&#xAE; (atezolizumab) as maintenance therapy for patients with extensive stage small cell lung cancer (ES-SCLC).
 &nbsp;

GNPX

Genprex Announces First Patient Enrolled In Acclaim-3 Phase 2 Study For ES-SCLC; 25 Patients To Complete Enrollment In H2 2025; Study Has FDA Orphan Drug And Fast Track Designations

During the last three months, 4 analysts shared their evaluations of CNO Finl Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNO#NYSE">CNO</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CNO Finl Group and provided 12-month price targets. The average target is $40.75, accompanied by a high estimate of $44.00 and a low estimate of $38.00. Observing a 5.38% increase, the current average has risen from the previous average price target of $38.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1737637261_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive CNO Finl Group is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Suneet Kamath</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$41.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CNO Finl Group. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CNO Finl Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of CNO Finl Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of CNO Finl Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CNO Finl Group analyst ratings.</a>
<h2>All You Need to Know About CNO Finl Group</h2>
CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
<h3>Breaking Down CNO Finl Group's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: CNO Finl Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.21%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: CNO Finl Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.82%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): CNO Finl Group's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.36%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): CNO Finl Group's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: CNO Finl Group's debt-to-equity ratio stands notably higher than the industry average, reaching 1.6. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNO Finl Group Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Throughout the last three months, 4 analysts have evaluated Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $17.0, a high estimate of $26.00, and a low estimate of $12.00. This upward trend is apparent, with the current average reflecting a 41.67% increase from the previous average price target of $12.00.
<img src="https://www.benzinga.com/files/images/story/2025/1737637245_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Altimmune among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Annabel Samimy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$26.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Altimmune. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Altimmune's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Altimmune's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About Altimmune</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>Altimmune's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Decline in Revenue: Over the 3 months period, Altimmune faced challenges, resulting in a decline of approximately -98.62% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Altimmune's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -456900.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Altimmune's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -14.22%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Barclays analyst Raimo Lenschow maintains SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) with a Overweight and raises the price target from $275 to $283.

Barclays Maintains Overweight on SAP, Raises Price Target to $283

TE Connectivity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEL#NYSE">TEL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for TE Connectivity, revealing an average target of $155.25, a high estimate of $168.00, and a low estimate of $137.00. Experiencing a 1.95% decline, the current average is now lower than the previous average price target of $158.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1737637229_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of TE Connectivity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luke Junk</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$168.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$151.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Stephen Bersey</td>
<td>HSBC</td>
<td>Announces</td>
<td>Reduce</td>
<td>$137.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TE Connectivity. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TE Connectivity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of TE Connectivity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of TE Connectivity's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TEL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TE Connectivity analyst ratings.</a>
<h2>Get to Know TE Connectivity Better</h2>
TE Connectivity is the largest electrical connector supplier in the world, supplying interconnect and sensor solutions to the transportation, industrial, and communications markets. With operations in 150 countries and over 500,000 stock-keeping units, TE has a broad portfolio that forms the electrical architecture of its end customers' cutting-edge innovations.
<h3>Understanding the Numbers: TE Connectivity's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: TE Connectivity's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 0.82%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: TE Connectivity's net margin excels beyond industry benchmarks, reaching 6.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): TE Connectivity's ROE excels beyond industry benchmarks, reaching 2.21%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): TE Connectivity's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.21% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: TE Connectivity's debt-to-equity ratio is below the industry average. With a ratio of 0.35, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 4 Analyst Projections For TE Connectivity

Alaska Air Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) short percent of float has fallen 32.71% since its last report. The company recently reported that it has 6.58 million shares sold short, which is 6.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.06 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Alaska Air Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737637224_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Alaska Air Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Alaska Air Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Alaska Air Gr's peer group average for short interest as a percentage of float is 8.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(ALK) - Analyzing Alaska Air Gr's Short Interest

Membership Int Ser 2019 Gibson Tony Iommi (Monkey Sg Guitar)

Comments

(AHLTS) Forecast

(OTC:AHLTS) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga